TP53 and diabetic cardiomyopathy: TMYXP exerts anti-CHD effects on the TNF signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway, MAPK signaling pathway, lipid and atherosclerosis, NOD-like receptor signaling pathway, diabetic cardiomyopathy and cytokine-cytokine receptor interaction.